Dr. Donington on the Role of Neoadjuvant Immunotherapy in Stage II NSCLC

Video

Jessica Donington, MD, MSCR, discusses the role of neoadjuvant immunotherapy in patients with stage II non–small cell lung cancer. 

Jessica Donington, MD, MSCR, professor of surgery and chief of the Section of Thoracic Surgery at the University of Chicago Medicine, discusses the role of neoadjuvant immunotherapy in patients with stage II non–small cell lung cancer (NSCLC).

Trials evaluating neoadjuvant immunotherapy in NSCLC included patients with stage II and stage III disease, says Donington. However, its role in patients with stage II disease is unclear.

It is not standard of care to give patients with stage II disease neoadjuvant chemotherapy prior to surgical resection, explains Donington. Instead, these patients typically undergo resection followed by adjuvant chemotherapy.

Until the field has long-term data with neoadjuvant immunotherapy, patients with stage II disease should continue to undergo up-front surgical resection, concludes Donington.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,